


**Influenza Activity Update (October 2011- January 2012):**

Overall influenza activity is at a low level so far during the 2011-12 season. According to the CDC, influenza A or B was detected in 4.9% of the 3,572 surveillance specimens tested. Of the specimens testing positive for influenza, the majority (83%) were influenza A (H3N2), and 5.1% were Influenza B. Influenza activity has been sporadic in Wisconsin (89% A/H3, and 11% 2009 A/H1N1) and the rest of the region V (WI, MN, IL, MI, OH, IN) states. Influenza-like Illness (ILI) activity is minimal in Wisconsin (of 422 tested by PCR, 15 positive for influenza; 3.6%). So far there are no positive influenza cases reported at MHD Laboratory (n= 58 tested by PCR). Due to the low prevalence, the Predictive Value Positive (PVP) for rapid influenza tests remains low. Any positive rapid influenza test should be confirmed by PCR, if available. Public Health agencies are also aware of periodic cases of swine-origin influenza A (H3) infection. All unsubtypeable cases or cases with unusual typing patterns should be forwarded to the MHDL or WSLH for confirmatory testing and necessary further analysis. The viruses currently circulating have been susceptible to the neuraminidase inhibitors (oseltamivir and zanamivir). However, these viruses have high levels of resistance to the adamantanes (amantadine and rimantadine).

**Respiratory Virus Surveillance:**

Respiratory Virus Panel Test Results		
Virus	Positives	Percent
Human Rhinovirus (HRV)	3	15.7%
Adenovirus	1	5.2%
Coronavirus (229E & NL 63)	2	10.5%

Samples tested: 19 (December, 2011- January, 2012)





## SUMMARY OF CONFIRMED INFECTIONS

Steve Gradus, PhD, D(ABMM)  
Laboratory Director

December 2011 Final, Vol. 16, No. 13

Sanjib Bhattacharyya, PhD  
Chief Molecular Scientist

This issue represents laboratory test data for December 2011.

### Syphilis

Test	Total	Test	Total
RPR Reactive	1	TPPA Reactive	9
VDRL Reactive	15	Darkfield Positive	0

### New Cases of Syphilis

Stage	Number of Cases	
	December 2011	December 2010
Primary syphilis	0	0
Secondary syphilis	2	0
Early latent	0	0
Late latent	1	0
Total	3	0

Source: Wisconsin Division of Health

### Gonorrhea Antimicrobial Susceptibility Testing

Number Tested	Decreased Susceptible (DS) / Resistant (R) Antibiotics			
	Ciprofloxacin	Cefixime	Ceftriaxone	Azithromycin
38	0	0	0	0

### Isolates Other Than *N. gonorrhoeae*

Organism	Site	Number Isolates	Organism	Site	Number Isolates
<i>Ureaplasma urealyticum</i>	Genital	7	<i>Mycoplasma hominis</i>	Genital	3

### Enteric Parasites Identified

Age	Sex	Parasite
24	M	<i>Blastocystis hominis</i>
29	M	<i>Blastocystis hominis</i>
		<i>Entamoeba coli</i>
9	M	<i>Blastocystis hominis</i>
		<i>Endolimax nana</i>
		<i>Entamoeba coli</i>
32	F	<i>Endolimax nana</i>
40	M	<i>Endolimax nana</i>
		<i>Entamoeba coli</i>
30	F	<i>Endolimax nana</i>
		<i>Entamoeba coli</i>
7	M	<i>Entamoeba coli</i>
		<i>Giardia lamblia</i>
9	F	<i>Entamoeba coli</i>
		<i>Giardia lamblia</i>
20	F	<i>Giardia lamblia</i>
3	F	<i>Giardia lamblia</i>
5	F	<i>Giardia lamblia</i>
		<i>Hymenolepis nana</i>
53	M	<i>Iodamoeba buetschlii</i>

### Mycobacterial Infections

Age	Sex	Test Results				Identification
		Sputum Smear	Culture	DNA Probe	PCR	
40	M	-	+	+	-	<i>M. avium</i> complex
42	M	-	+	+	-	<i>M. avium</i> complex
20	F	+	+	+	ND	<i>M. avium</i> complex

### Reference Cultures

Age	Sex	Source	Identification
22	M	Urethra	<i>Neisseria gonorrhoeae</i>
19	F	Cervix	<i>Neisseria gonorrhoeae</i>
22	M	Throat	<i>Neisseria meningitidis</i>
22	F	Throat	<i>Neisseria meningitidis</i>
18	F	Stool	<i>Salmonella</i> Enteritidis
62	M	Stool	<i>Salmonella</i> Schwarzengrund

### Virus Isolations from Clinical Specimens

Age	Sex	Source	Symptoms	Agent
18	F	NP	Myalgia, cough, sore throat, nausea/vomiting, headache	Adenovirus
2m	M	NP	Autopsy	Rhinovirus
93	F	Stool	Diarrhea	Norovirus genogroup II
90	F	Stool	Diarrhea	Norovirus genogroup II
93	F	Stool	Diarrhea	Norovirus genogroup II
29	M	Forehead	Vesicular lesion	Varicella-Zoster Virus
33	M	Flank, R	N/A	Varicella-Zoster Virus
20	M	Back	N/A	Varicella-Zoster Virus

### Herpes Simplex Virus Isolations

Agent	Number of Isolates
Herpes Simplex type 1	6
Herpes Simplex type 2	7

### Molecular Amplification and PCR

Agent	Method	Tested	Positive	% Positive
<i>Bordetella pertussis/parapertussis</i>	RT-PCR	4	0	0%
Influenza virus	RT-PCR	9	0	0%
Norovirus	RT-PCR	8	3	38%
Herpes Simplex Virus	RT-PCR	2	1	50%

### Chlamydia (CT) and Gonorrhea (GC) Molecular Testing

Source	Tested	Positive	% Positive
Urine	571	84 (CT)	14.7%
		46 (GC)	8.1%
Throat swabs	229	4 (CT)	1.7%
		10 (GC)	4.4%
Rectal swabs	30	4 (CT)	13.3%
		3 (GC)	10.0%
Genital swabs	2	0 (CT)	0%
		1 (GC)	50%

**DNA Sequencing:** The MHD laboratory uses 16S rRNA and the D2 region of the 26S rRNA genes for DNA sequence-based microbial identification of selective reference bacteria and fungal isolates

Reference Microbe	Age	Sex	Source	Target gene	Final Identification
Bacteria	56	F	Brain	16S rRNA	<i>Lactobacillus rhamnosus</i>
			Lung		<i>Lactococcus lactis</i>